Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma
British Journal of Clinical Pharmacology · 16.11.2026
DOI: 10.1002/bcp.70918 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 16.11.2026. Verfasst von Maud Maillard und 20 weiteren Autor:innen. Beteiligte Einrichtung: Univ Toulouse, Oncopole-Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancéropole GSO, Conseil Scientifique ICR 2011, French Ministry of Health.
Abstract (Originalsprache)
Aim
Sunitinib and pazopanib are anti‐angiogenic tyrosine kinase inhibitors (TKIs) used for metastatic renal cancer, with substantial interindividual variability in drug response. This study aimed to explore factors explaining this variability.
Methods
Pharmacokinetics (PK) and pharmacogenomics (PG) data from 47 patients enrolled in the SUP‐R clinical trial (NCT02555748) were analysed retrospectively (32 treated with sunitinib, 15 with pazopanib). Plasma concentrations measured during the first two treatment cycles were analysed using a non‐linear mixed effects model. Exploratory analyses of factors influencing drug exposure, toxicity and efficacy were conducted, including a PG investigation of drug disposition, and target genes and baseline circulating microRNA levels. No correction for multiple comparisons was applied.
Results
The PK models adequately described plasma concentration over time in the cohort. Patients experiencing severe toxicity (≥ Grade 3, CTCAE) showed reduced apparent sunitinib clearance (median 24.3 L/h [11.1–45.7] vs . 32.4 L/h [16.6–90.6], p = 0.006). Responders were more exposed to sunitinib and active metabolite SU12662 (observed C trough,ss = 140.1 ng/mL [43.2–209.5] vs . 89.5 ng/mL [4.3–230.7], p = 0.036); similar trends were observed with pazopanib, though limited events (3 responders/10 evaluable) precluded definitive interpretation. Carriers of at least one variant ABCB1 c.1199G>A allele were more likely to respond to TKI treatment (odd‐ratio = 10.8, 95% confidence interval [1.7–69.9], p = 0.012).
Conclusion
This study assessed the exposure‐response relationships of both drugs and identified potential factors to consider in case of toxicity or treatment failure.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Univ Toulouse, Oncopole-Claudius Regaud, IUCT-Oncopole, Inserm, CRCT, Toulouse, France.
- Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Biostatistics & Health Data Science Unit, Toulouse, France.
- Univ Toulouse, Inserm, CRCT, Toulouse, France.
- Faculté de Pharmacie, University of Montréal, Montréal, Québec, Canada.
- Institut Régional Du Cancer de Montpellier, Montpellier, France.
- Department of Medical Oncology, Institut Paoli-Calmettes, Aix Marseille Univ, INSERM, CNRS, CRCM, Immunity and Cancer Team, Marseille, France.
ORCID-Profile: Maud Maillard, Matthieu Gracia, Bastien Cabarrou, Félicien Le Louedec, Mathieu Landry, Deniz Ozdin, Ben Allal, Diego Tosi, Gwenaelle Gravis, Guilhem Roubaud, Frédéric Thuillier, Helen Boyle, Florent Puisset, Mélanie White-Koning, Etienne Chatelut, Loïc Mourey, Fabienne Thomas
Förderung
- Cancéropole GSO
- Conseil Scientifique ICR 2011
- French Ministry of Health
Zitieren
APA
Maillard, M., Gracia, M., Cabarrou, B., Le Louedec, F., Moreau, C., Landry, M., Brice, A., Lafont, T., Ozdin, D., Allal, B., Tosi, D., Gravis, G., Roubaud, G., Thuillier, F., Boyle, H., Puisset, F., White-Koning, M., Pradines, A., Chatelut, E., …, & Thomas, F. (2026). Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70918
Vancouver
Maillard M, Gracia M, Cabarrou B, Le Louedec F, Moreau C, Landry M, et al. Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70918
BibTeX
@article{Maillard2026,
author = {Maillard, Maud and Gracia, Matthieu and Cabarrou, Bastien and Le Louedec, Félicien and Moreau, Christelle and Landry, Mathieu and Brice, Aurélie and Lafont, Thierry and Ozdin, Deniz and Allal, Ben and Tosi, Diego and Gravis, Gwenaelle and Roubaud, Guilhem and Thuillier, Frédéric and Boyle, Helen and Puisset, Florent and White-Koning, Mélanie and Pradines, Anne and Chatelut, Etienne and Mourey, Loïc and Thomas, Fabienne},
title = {Integrated evaluation of pharmacokinetics and pharmacogenomics of sunitinib and pazopanib in patients with metastatic renal carcinoma},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70918}
}
EUVIMED